TC
ELV icon

Trilogy Capital’s Elevance Health ELV Stock Holding History

Trilogy Capital’s Portfolio ELV Stock Details ELV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-574
Closed -$271K – 306
2023
Q4 		$271K Sell
574
-130
-18% -$60.1K 0.02% 220
2023
Q3 		$306K Sell
704
-86
-11% -$39K 0.02% 192
2023
Q2 		$376K Buy
790
+37
+5% +$17.1K 0.02% 195
2023
Q1 		$346K Buy
753
+142
+23% +$67.6K 0.02% 187
2022
Q4 		$313K Buy
611
+117
+24% +$59.4K 0.02% 193
2022
Q3 		$224K Buy
+494
New +$236K 0.02% 165
2019
Q1 		– Sell
-1,199
Closed -$315K – 133
2018
Q4 		$315K Sell
1,199
-253
-17% -$69.6K 0.04% 104
2018
Q3 		$398K Sell
1,452
-252
-15% -$65.4K 0.05% 98
2018
Q2 		$406K Sell
1,704
-246
-13% -$57K 0.05% 86
2018
Q1 		$428K Buy
+1,950
New +$458K 0.06% 85

Other funds holding ELV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Trilogy Capital's ELV Position: Q1 2024 in Review

Trilogy Capital sold out of Elevance Health (ELV) in Q1 2024, closing a stake of 574 shares — an estimated $271K sold.

Trilogy Capital first reported a position in ELV in Q1 2018 and held it in 10 quarters. The position peaked at $428K in Q1 2018. 1,666 funds tracked by Wall St. Rank hold ELV as of Q1 2024.

  • Trilogy Capital reported no remaining Elevance Health position as of Q1 2024 after selling out during the quarter.
  • Trilogy Capital sold 574 Elevance Health shares in Q1 2024, an estimated $271K.
  • Trilogy Capital first reported a position in Elevance Health in Q1 2018 and held it in 10 quarters.
  • Trilogy Capital's Elevance Health position peaked at $428K in Q1 2018.
  • 1,666 funds tracked by Wall St. Rank held Elevance Health as of Q1 2024.

Based on Trilogy Capital's 13F filing for Q1 2024, filed 17 Apr 2024.